AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06333730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar nerve block
Description: After informed consent, the needle will be inserted into the muco-buccal fold adjacent to the mandibular molars and advanced it towards the mandibular foramen, aiming slightly anteriorly and superiorly. Aspirating to check for blood or resistance, the needle will be repositioned if either was present. Once the needle will be correctly positioned, the dental practitioner will slowly inject 1.8-1.9 mL of the anesthetic solution.
Study NCT06333730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mental nerve block
Description: After informed consent, the needle will be inserted into the buccal fold between the lower premolars. Aspirating to check for blood or resistance. Once needle is correctly positioned, 0.6-0.9 ml of the anesthetic solution will be deposited.
Study NCT04856111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Same as arm description
Study NCT04856111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Same as arm description
Study NCT05405790 — intervention group
Intervention type: PROCEDURE
Intervention: thoracic endovascular aortic repair
Description: In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
Study NCT05001607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bronchial Blocker
Description: Trial of four methods of pulmonary blockade; one novel method and three published methods.
Study NCT05931536 — intervention group
Intervention type: OTHER
Intervention: Dietary fibre
Description: Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
Study NCT04980027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (U300)
Description: Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
Study NCT05622916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Ethanol Extract (Piper crocatum)
Description: Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
Study NCT05622916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trichloroacetic Acid Topical
Description: Trichloroacetic acid topical 90%
Study NCT04931368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
Description: De-escalated induction treatment with R/HD-MTX and two courses of MATRix
Study NCT04931368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention: four courses of MATRix
Description: Patients receive four courses of MATRix as induction treatment.
Study NCT05433467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided localization for micro hepatocellular carcinoma before surgical resection
Description: After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
Study NCT05620589 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin + Tetracycline + Bismuth + Esomeprazole
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
Study NCT05620589 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin + Tetracycline + Bismuth + Vonoprazan
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
Study NCT05620589 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin + Tetracycline + Bismuth + Tegoprazan
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
Study NCT05155332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169
Study NCT05155332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: anti-PD-1 antibody
Study NCT06518031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meditation
Description: meditation practices were administered by the meditation expert for 6 weeks, three times a week for 20 minutes each session, totaling 60 minutes per week
Study NCT06341686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 480 MG
Description: Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection
Study NCT06341686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: The threshold for starting treatment with Ganciclovir is a CMV DNAemia > 5,000 IU in a single measurement (CMV infection) measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).
Study NCT01996462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets
Study NCT05435482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive two small group meetings and two follow-up calls
Study NCT05435482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 testing kits
Description: Participants will receive two COVID-19 at-home antigen test kits.
Study NCT05435482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 testing kits
Description: Participants will receive two COVID-19 at-home antigen test kits.
Study NCT05435482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instruction
Description: Participants will receive a written guide and a video clip guide to the test kit.
Study NCT05435482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction
Description: Participants will receive a written guide and a video clip guide to the test kit.
Study NCT05716724 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
Study NCT06507462 — intervention group
Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: All patients were required to underwent transperineal prostate biopsy and have corresponding pathological diagnosis results.
Study NCT05047718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine Pfizer (3 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
Study NCT05047718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine Pfizer (2 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
Study NCT05047718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine Moderna (3 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
Study NCT05047718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine Moderna (2 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
Study NCT05047718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine Moderna (1 dose)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
Study NCT04730193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
Study NCT04730193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill will be formulated with a non active ingredient such as rice flour powder
Study NCT05248126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard patient education
Description: The comparator intervention is the usual therapeutic training for patients (ETP) cursus currently used in the General Pulmonology unit at the Arnaud De Villeneuve Hospital, Montpellier, France and approved by the French Regional Health Authority for the Occitanie Region \[Agence Régional de Santé Occitanie\].
Study NCT05248126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot patient education
Description: The experimental intervention consists in providing the patient with access to a specific version of the Vik-Asthme chat bot for the duration of the study. Should the patient be unable to use or refuse to use the chatbot, the reasons for refusal will be documented and the patient will proceed with the comparator intervention.
Study NCT06398886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ericksonian Hypnosis
Description: The Ericksonian hypnosis intervention was designed to create a nurturing and therapeutic setting, specifically tailored to the unique challenges of prolonged grief faced by university students. This approach focused on accessing the subconscious, using symbolic and imaginative techniques to facilitate change. The goal was to alleviate the emotional pain associated with prolonged grief and to empower students to adapt more effectively to their loss. This intervention highlighted the transformative potential of Ericksonian methods in addressing deep-seated emotional issues through gentle and indirect therapeutic modalities.
Study NCT06398886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ericksonian Hypnosis
Description: The Ericksonian hypnosis intervention was designed to create a nurturing and therapeutic setting, specifically tailored to the unique challenges of prolonged grief faced by university students. This approach focused on accessing the subconscious, using symbolic and imaginative techniques to facilitate change. The goal was to alleviate the emotional pain associated with prolonged grief and to empower students to adapt more effectively to their loss. This intervention highlighted the transformative potential of Ericksonian methods in addressing deep-seated emotional issues through gentle and indirect therapeutic modalities.
Study NCT06398886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention aimed to provide a supportive and healing environment, addressing the specific challenges of prolonged grief within a university student population. The focus was on developing concrete skills to manage the cognitive and behavioral aspects of grief. This approach sought to mitigate the pain of prolonged grief and empower students to adapt more healthily to their loss, emphasizing practical strategies for change and coping. Participants were encouraged to actively engage in exercises that challenged their thought patterns and promoted behavioral adjustments tailored to their individual needs.
Study NCT06398886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention aimed to provide a supportive and healing environment, addressing the specific challenges of prolonged grief within a university student population. The focus was on developing concrete skills to manage the cognitive and behavioral aspects of grief. This approach sought to mitigate the pain of prolonged grief and empower students to adapt more healthily to their loss, emphasizing practical strategies for change and coping. Participants were encouraged to actively engage in exercises that challenged their thought patterns and promoted behavioral adjustments tailored to their individual needs.
Study NCT02974777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT reduction
Description: Reduction of standard dose DAPT due to low platelet reactivity
Study NCT02974777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT on-target
Description: Standard DAPT within the therapeutic window of platelet reactivity
Study NCT02974777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT intensification
Description: Intensification of standard dose DAPT due to high platelet reactivity
Study NCT05048498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEX-18a injection
Description: In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection.
Study NCT05048498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine Injection
Description: In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
Study NCT06107868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.
Study NCT06107868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an antineoplastic agent.
Study NCT06107868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent.
Study NCT04387500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab injection plus Inlyta treatment
Description: Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC
Study NCT05854407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: skim milk
Description: pasteurized or high-pasteurized skim milk
Study NCT05905627 — intervention group
Intervention type: BEHAVIORAL
Intervention: exercise
Description: intervention group
Study NCT05263674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid sedation
Description: High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
Study NCT05943366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keep-on-Keep-Up Nutrition (KOKU-Nut)
Description: Keep-on-Keep-Up (KOKU) is a free, tablet-based strength and balance exercise application that was soft launched in 2020 (https://kokuhealth.com/). KOKU is approved by the National Health Service (NHS) and Organisation for the Review of Care and Health Apps (ORCHA) as a lifestyle app and has been viewed positively by older adults after 6 weeks of independent use. KOKU-Nut is the latest development of this interactive platform and includes nutritional games based on the UK dietary guidelines to nudge older adults to improve their diet with a specific focus on protein, fibre and fluid.
Study NCT05857761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Description: Five sessions of active rTMS therapy will be distributed over 2 weeks (20 Hz, 2000 pulses, 90% resting motor threshold) will be delivered to left dorsolateral pre-frontal cortex (DLPFC) around 6 months post-trauma.
Study NCT05857761 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Five sessions of sham rTMS therapy will be distributed over 2 weeks
Study NCT06441318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Povorcitinib will be administered at protocol defined dose.
Study NCT06441318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered at protocol defined dose.
Study NCT06441318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at protocol defined dose.
Study NCT05816772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endosequence Bio ceramic Sealer
Description: Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide
Study NCT05816772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealapex Calcium hydroxide Based Sealer
Description: KERR Dental, an original eugenol-free root canal sealant based on calcium hydroxide.
Study NCT06441318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered at protocol defined dose.
Study NCT04940338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic 0.09% Ophthalmic Solution
Description: topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery
Study NCT04940338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic
Description: topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery
Study NCT04940338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical placebo (artificial tears substitute) 2x daily before the surgery
Study NCT04940338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery (PHACO)
Description: About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).
Study NCT04940338 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Phacoemulsification surgery (PHACO)
Description: About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).
Study NCT06401070 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plesterin
Description: The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
Study NCT06401070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press needle acupuncture
Description: Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
Study NCT05732753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + Education in Neurophysiology of pain
Description: An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
Study NCT05732753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness + Education in Neurophysiology of pain
Description: An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
Study NCT06332196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample and clinical data
Description: Analysis of biological sample and clinical data
Study NCT05259826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy sampling
Description: 1. Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~2. Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression.
Study NCT05200273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK114
Description: AK114 administered by subcutaneous injection